Aldevron
Buying intent
28 tracked signals | Top 15 topics are below | Sales and Marketing are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Aldevron's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
24d ago
24d ago
19d ago
19d ago
25d ago
25d ago
17d ago
19d ago
18d ago
17d ago
24d ago
26d ago
10d ago
17d ago
10d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Aldevron
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
See everyone, not just the first 10
11 people across every department at Aldevron, plus a LinkedIn profile link for each.
Primary products / business lines
LinkedIn company profileAldevron is proud to be part of Danaher. Danaher’s science and technology leadership puts Aldevron’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock
Top accounts researching Aldevron
names withheld on the public pageThese are companies whose own people brought up Aldevron unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
6,459 companies · 25,813 people are researching Pharmaceutical
Aldevron's own team shows 4 signals on this topic. No one outside Aldevron has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Gene Therapy675 cos · 1,971 people
- Cell Therapy523 cos · 1,729 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Sales — 4 people; Marketing — 1 person; Leadership — 1 person
What's been said
public posts mentioning AldevronUp to 9 public excerpts naming Aldevron from the past 365 days, across LinkedIn, Reddit, X, YouTube and other public sources.
Partnerships like this don't happen overnight and they don't move forward without real alignment. At ASGCT, Emma Bjorgum (Aldevron) and Francesca Vitelli (Minaris Advanced Therapies) took a moment to share their excitement. This collaboration is about expanding access to lentiviral plasmids in a way that actually reduces complexity for developers. The goal is simple: make it easier to move from discovery into the clinic with greater consistency, fewer bottlenecks, and materials that are ready to scale when it matters most. #ASGCT #CellAndGeneTherapy #Biomanufacturing #LentiviralVectors
May 2026Ex-vivo LVV? In-Vivo LVV? This collaboration between Aldevron and Minaris Advanced Therapies gives our program sponsors access to Off-the-shelf material that is proven in clinical trials and best in class LVV titiers. Why spend the time and money optimizing your LVV packagers..? We have you covered - oh and custom GOI, in Reseach Grade through GMP, of course we have you covered there too! “A World where every cure is possible” - Aldevron
May 2026Moments like this highlight the importance of scalable, high-quality manufacturing in bringing breakthrough science to life. Honored that Aldevron teams could help accelerate such a meaningful advance. ---- Baby KJ was born with a rare, potentially fatal genetic disease with limited treatment options and significant uncertainty. In response, the world's first personalized CRISPR‑based therapy was designed, manufactured, and administered to him in record time. That effort is why teams from Children's Hospital of Philadelphia, Penn Medicine, University of Pennsylvania Health System, Innovative Genomics Institute, and Danaher Corporation received the ASGCT Catalyst Award this week at #ASGCT2026 . The work moved forward because people across medicine, academia, and industry stayed aligned on one outcome: turning a one‑of‑a‑kind scientific idea into a treatment for a child who needed it now. Doing that required coordination across research, manufacturing, and clinical care, with no precedent and no margin for delay. Danaher Life Sciences businesses Aldevron and Integrated DNA Technologies manufactured key components of this highly complex, personalized gene editing therapy at speed, with Aldevron producing the final drug product. Congratulations to the teams whose collaboration made this possible, and to the broader cell and gene therapy community advancing what can be delivered when expertise, scale, and urgency come together.
May 2026The announced partnership with Minaris below, is yet another example how Aldevron is uniquely positioned to support our program sponsors in a way no other CDMO is able, across multiple modalities and quality grades. With the Minaris partnership, Aldevron continues to support LVV / GMCT plasmid needs, from Discovery to Commercialization - No other CDMO has done more RG plasmid lots, and no one has more commercial products supported, outside Aldevron. “A world where every cure is possible” - Aldevron
May 2026Looking forward to connecting with all of you at ASGCT. I’m spending time at the Danaher booth (1337) alongside the Aldevron team. These conversations—across research, development, and manufacturing—are where real progress happens and impact is delivered at every stage. If you’re attending, feel free to stop by and say hello. 🔗 https://lnkd.in/ebXajcq2 #ASGCT #GeneTherapy #CellTherapy #ATMP #BiotechEvents
May 2026Early decisions in mRNA development have long‑term consequences. Join Aldevron for an upcoming webinar, Start Right. Scale Right: Scaling mRNA Therapeutics from Research‑Grade to cGMP, focused on the inflection points that can either accelerate progress or introduce comparability, regulatory, and scalability challenges. This session will explore: ✅Phase‑appropriate decisions for linear DNA templates, IVT, and analytics ✅Common scale‑up pitfalls such as variability, dsRNA formation, and material mismatches ✅How aligning research‑stage methods with cGMP realities can de‑risk tech transfer and clinical transitions Catch our webinar on May 20. Register now: https://ald.bio/4cvnIOX #mRNA #cGMP #GeneTherapy #Biomanufacturing #ProcessDevelopment
May 2026We are thrilled to renew Aldevron’s partnership with Minaris for access to lentiviral plasmids at any stage of development!
May 2026